Audentes Therapeutics (BOLD) Tops Q1 EPS by 6c
Tweet
Share
E-mail
Get Alerts BOLD Hot Sheet
Join SI Premium – FREE
Audentes Therapeutics (NASDAQ: BOLD) reported Q1 EPS of ($0.74), $0.06 better than the analyst estimate of ($0.80).
For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
- The LGL Group (LGL) Misses Q2 EPS by 8c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
